Prostate cancer, often developing insidiously over many years, poses a unique challenge. While many men live with indolent forms requiring minimal intervention, a subset faces aggressive variants that recur even after surgical removal of the tumor. Differentiating these phenotypes early has remained elusive, primarily due to an incomplete understanding of the molecular drivers governing tumor progression and recurrence. The NTNU research team addressed this by analyzing carefully preserved prostate tissue samples extracted from patients with well-documented clinical outcomes, some spanning retrospective follow-up periods exceeding a decade.

The cornerstone of this insight was identifying a unique gene expression signature inherent to the aggressive prostate tumors themselves. By mapping transcriptomic data onto spatial tissue architecture, the team delineated specific gene activation patterns predictive of recurrence and metastatic potential. This molecular fingerprint offers a promising biomarker panel that clinicians could employ to distinguish patients necessitating intensive therapy from those with more indolent disease courses, thereby enabling precision medicine in prostate cancer management.

Beyond the tumor margins, the normal-appearing adjacent prostate tissue exhibited profound metabolic and immunologic alterations, underscoring the concept that cancer’s influence pervades the surrounding microenvironment. Intriguingly, these benign regions manifested signs of chronic inflammation characterized by elevated neurotransmitters that attract immune effector cells and an increased presence of inflammatory cell subtypes capable of perpetuating immune reactions. Concurrently, essential metabolic compounds showed significant depletion, reflecting a loss of physiological glandular function — a hallmark of disrupted homeostasis in cancer proximate tissues.

This inflammatory milieu adjacent to the tumor may not simply be a bystander effect but could actively foster tumor progression and resistance to therapy. The study hypothesizes that the crosstalk between malignant cells and the inflamed stroma creates a niche conducive to cancer aggressiveness. Such findings add a new dimension to the current understanding of prostate cancer pathophysiology and open avenues for therapies targeting the microenvironment to prevent disease escalation.

Clinically, prostate cancer screening predominantly relies on digital rectal examinations and serum prostate-specific antigen (PSA) levels. While PSA testing has markedly increased early detection rates, this method falls short in stratifying risks accurately, leading to overtreatment in many cases, a concern given potential side effects like incontinence, erectile dysfunction, and psychological distress. NTNU’s novel findings pave the way for more nuanced diagnostic tools that could potentially reduce unnecessary interventions by pinpointing aggressive cancers with higher precision.

The research utilized human prostate tissue samples collected meticulously and analyzed retrospectively, emphasizing the laborious nature of longitudinal cancer research where outcomes like relapse may take nearly a decade to manifest. This persistence highlights the dedication essential for translating biological markers into clinically actionable data, underscoring the value of biobanking and long-term patient follow-up in oncological studies.

Advanced imaging with MRI remains a cornerstone in prostate cancer evaluation, offering detailed anatomical visualization. However, it lacks the molecular detail revealed by multi-omic profiling. The integration of molecular data with imaging could revolutionize prostate cancer diagnostics, shifting from solely structural assessments to comprehensive molecular characterizations, enabling earlier and more accurate identification of tumors likely to recur or metastasize.

At the forefront of this research, Sebastian Krossa notes the challenges in patient compliance with traditional exams and envisages a future where non-invasive screening through blood or sperm samples could be feasible. Such advancements would drastically lower barriers to detection and allow for timely interventions without discomfort or stigma associated with current sampling methods.

The importance of preventing overtreatment is a focal point in this research narrative. By better characterizing the aggressive subset of prostate cancers, clinicians can avoid the pitfalls of blanket treatment approaches and instead tailor interventions, thus preserving quality of life for patients with less severe disease. Reducing unnecessary therapy-related morbidity remains a critical challenge in oncology, and this study provides a vital piece to that puzzle.

The application of spatially resolved multi-omics represents a paradigm shift — moving from bulk tissue analyses toward decoding the intricate heterogeneity within tumors and adjacent tissues. This three-dimensional mapping grants unprecedented insights into cellular interactions and metabolic networks within the tumor microenvironment, a frontier that promises to redefine cancer biology.

Funded by the European Research Council’s Starting Grant, the NTNU team’s work exemplifies how foundational basic science research fuels clinical innovation. The integration of transcriptomic and metabolomic profiling with histopathological context yields comprehensive snapshots of cancer complexity, essential for healing advancements that extend beyond current standards of care.

In sum, these discoveries not only deepen scientific understanding of prostate cancer aggressiveness but also herald the development of next-generation diagnostic assays and personalized medicine strategies. The convergence of spatial biology, immunology, and metabolomics underscores a multifaceted attack on prostate cancer, equipping the medical community with tools to better predict, monitor, and treat this common yet heterogeneous disease.

Subject of Research: Human tissue samples

Article Title: Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment

News Publication Date: 19-Nov-2025

Web References:
http://dx.doi.org/10.1038/s41467-025-65161-9

References:
Krossa, S., Andersen, M.K., Sandholm, E.M. et al. Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment. Nat Commun 16, 10160 (2025).

Image Credits:
Photo: Anne Sliper Midling / NTNU

Keywords: Prostate cancer, aggressive tumor signature, spatial multi-omics, transcriptomics, metabolomics, tumor microenvironment, inflammation, biomarkers, cancer recurrence, personalized medicine

Prostate cancer, a leading health concern, poses critical challenges due to its prevalence and the difficulties associated with early diagnosis. Presently, the gold standard for diagnosing prostate cancer involves invasive biopsy procedures that can be uncomfortable and anxiety-inducing for patients. Traditionally, screenings utilize prostate-specific antigen (PSA) blood tests, yet these are not foolproof. The reliability of PSA tests is hampered by a variety of factors unrelated to cancer, including age, inflammation, and benign prostatic hyperplasia, often leading to false positives and unnecessary biopsies which create an additional mental burden for patients.

Aiming to tackle these pressing issues, Prof. Vellaisamy and his research team have engineered a highly selective system capable of detecting urinary biomarkers pertinent to prostate cancer. Central to this innovative screening technology is a cost-effective electrode suffused with a specially formulated coating consisting of organic monomers and crosslinking agents. This precisely engineered layer forms specific recognition sites designed to capture target biomolecules associated with prostate cancer, creating a comprehensive detection system that can simultaneously analyze multiple cancer biomarkers.

The revolutionary nature of this screening technology lies not only in its design but also in the sophisticated application of advanced machine learning methodologies, which enhance the accuracy of diagnostic results. This informed approach enables the system to function as a powerful diagnostic tool, capable of performance metrics on par with established medical benchmarks, demonstrating an impressive reliability that could dramatically enhance patient outcomes in prostate cancer detection.

The pivotal technology licensing agreement with Pinpoint Medical Ltd serves as an essential step toward transforming laboratory advancements into practical applications that benefit clinical practices. As the platform evolves into a portable, point-of-care diagnostic initiative, it promises to streamline the processes around diagnosing prostate cancer, thereby alleviating burdens on both medical providers and patients alike.

Understanding the urgency surrounding prostate cancer, it is noteworthy that it ranks as the second most diagnosed cancer among men worldwide and is responsible for a substantial number of cancer-related deaths. Consequently, there exists a pressing need for more effective and user-friendly screening methodologies that can facilitate prompt and accurate diagnosis. Prof. Vellaisamy emphasizes that this technology aims to provide an alternative to conventional, invasive testing methods, enabling clinicians to perform analyses on-site and democratizing access to early cancer diagnostics.

The ingenuity of this technology also has implications beyond prostate cancer. Prof. Vellaisamy anticipates future adaptations for bladder cancer detection, further illustrating the versatility and significance of this diagnostic innovation. As research continues to forge ahead, the impact of this technology could extend its utility, offering broader applications in various health sectors.

Highlighting the broader implications of this licensing agreement, Prof. Ricky Kwok Yu-kwong, the Vice President for Research and Institutional Advancement at HKMU, affirms the university’s mission to cultivate impactful research that aligns with societal needs. This initiative represents more than just a commercial venture; it embodies the university’s dedicated commitment to translating scientific discoveries into tangible benefits for the community, enhancing the quality of life through tailored medical solutions.

With the completion of its first technology licensing agreement, HKMU underscores its growing presence within the academic and research landscape. The university’s intellectual property portfolio has expanded significantly, indicating a robust trajectory toward fostering innovative advancements. As it continues to cultivate a culture of applied research, HKMU is poised to catalyze progress across various fields, heralding a new era of knowledge transfer and the practical application of scientific findings.

The prospects surrounding this novel technology are uplifting, providing hope to clinicians and patients alike. The possibility of harnessing a non-invasive, accurate diagnostic system could ultimately redefine the landscape of prostate cancer screening, empowering timely interventions and improving patient outcomes. With a strong foundation laid in research and a clear strategic path forward, HKMU is rendering valuable contributions to the ever-evolving fight against cancer.

As the world stands on the cusp of remarkable breakthroughs in medicine and diagnostics, this technology licensing agreement serves as a beacon of innovation, showcasing how academic research can parallel advances in clinical practice. The collaboration with Pinpoint Medical Ltd consolidates the vision of crafting a more efficient, accessible, and patient-centric approach to diagnosing one of the most prevalent cancers affecting men today.

Ultimately, this significant milestone not only celebrates HKMU’s achievements in technology transfer but also reinforces the enduring importance of academia-industry partnerships in addressing global health challenges. By bridging the gap between research and application, this agreement stands testament to the pivotal role that universities play in shaping the future of healthcare.

As the journey continues, the potential impacts of this electrochemical screening technology will unfold, leading to a new frontier in medical diagnostics that prioritizes patient welfare while paving the way for innovative solutions to critical health issues. The future holds promising avenues for greater diagnostic accuracy and patient-centered care in the landscape of prostate cancer screening.

Subject of Research: Prostate cancer screening technology
Article Title: HKMU Achieves First Technology Licensing Agreement for Non-Invasive Prostate Cancer Screening Innovation
News Publication Date: October 2023
Web References: https://www.hkmu.edu.hk/news/hkmus-first-technology-licence-paving-the-way-for-the-commercialisation-of-non-invasive-prostate-cancer-screening-innovation/
References: ACS Omega, ACS Sensors
Image Credits: Credit: Hong Kong Metropolitan University

Keywords

Prostate cancer, diagnostic technology, HKMU, electrochemical screening, technology licensing, urine test, biomarkers, medical research.